BioInvent International AB is a Pharmaceuticals company based in Sweden, specializing in developing novel immuno-modulatory antibodies for cancer therapy. With a medium risk ESG score of 26.3, the company has four drug candidates in ongoing clinical programs for hematological cancer and solid tumors. BioInvent utilizes its F.I.R.S.T technology platform to identify targets and antibodies, creating a strong pipeline for clinical development and partnership opportunities. Notable candidates include BI-1206 for non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 for solid cancers.